Bioequivalence study results for Alpha-1062 – August 2022. For the second quarter of 2022 versus the same prior year period, both ending June 30. No revenues were generated in either period; ...

This study was designed to investigate, in accordance with international regulatory guidelines, the bioequivalence of two omeprazole products following single- and multiple-dose administration, as ...

Spaulding Clinical to Perform Bioequivalence Study for One of World’s Largest Pharmaceutical Companies. September 13, 2010 02:26 PM Eastern Daylight Time. WEST BEND, ...

FDA now recommends only one study to show bioequivalence for certain oral drug products - FDA also revises several hundred product specific guidances to align with ICH M13A BE standards ...

Bioequivalence was accepted if the calculated 90%-confidence intervals were within 0.80 - 1.25 for AUC t and within 0.75 - 1.33 for C max. Possible side effects of the study medication and any ...

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease. August 22, 2022 09:00 AM Eastern Daylight Time.

In a bioequivalence study conducted in 75 human subjects, ET-600 showed pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient.

Completed dosing of 3 of 4 planned cohorts; expect to complete study in the second quarter of 2023 BOSTON and ATLANTA, March 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT ...

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient ...

BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party ...

REDWOOD CITY, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence ...